PriceTargets.com logo

Mirum Pharmaceuticals - MIRM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $84.91
  • Forecasted Upside: 18.70%
  • Number of Analysts: 14
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 11 Buy Ratings
  • 2 Strong Buy Ratings
$71.53 As of 12/4/2025 05:00 PM ET
▲ +0.54 (0.76%)

This chart shows the closing price for MIRM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mirum Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MIRM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MIRM

Analyst Price Target is $84.91
▲ +18.70% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is $84.91, with a high forecast of $95.00 and a low forecast of $55.00. The average price target represents a 18.70% upside from the last price of $71.53.

This chart shows the closing price for MIRM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 14 investment analysts is to buy stock in Mirum Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 2 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 2 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 2 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 2 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 2 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 2 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/5/2025Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$85.00 ➝ $95.00
11/5/2025HC WainwrightBoost TargetBuy ➝ Buy$80.00 ➝ $81.00
11/5/2025JMP SecuritiesSet Target$95.00
11/5/2025CitigroupReiterated RatingOutperform ➝ Outperform
11/5/2025Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$81.00 ➝ $95.00
10/16/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$75.00 ➝ $81.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/25/2025TD CowenUpgradeStrong-Buy
9/24/2025CowenInitiated CoverageBuy
9/24/2025TD CowenInitiated CoverageBuy$95.00
9/12/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$53.00 ➝ $77.00
8/11/2025Stifel NicolausSet TargetBuy$89.00
8/8/2025Evercore ISIBoost TargetOutperform ➝ Outperform$77.00 ➝ $89.00
8/7/2025Raymond James FinancialReiterated RatingStrong-Buy ➝ Strong-Buy
8/7/2025JMP SecuritiesSet TargetMarket Outperform ➝ Market Outperform$79.00 ➝ $81.00
8/7/2025Raymond James FinancialBoost TargetStrong-Buy ➝ Strong-Buy$77.00 ➝ $82.00
8/7/2025HC WainwrightBoost TargetBuy ➝ Buy$73.00 ➝ $80.00
7/11/2025Evercore ISIReiterated RatingOutperform ➝ Outperform
5/19/2025HC WainwrightReiterated RatingBuy$73.00
5/13/2025Raymond James FinancialReiterated RatingStrong-Buy ➝ Strong-Buy
5/13/2025Raymond James FinancialBoost TargetStrong-Buy ➝ Strong-Buy$73.00 ➝ $77.00
5/9/2025JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$74.00 ➝ $76.00
2/28/2025HC WainwrightBoost TargetBuy ➝ Buy$66.00 ➝ $72.00
2/27/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$50.00 ➝ $55.00
11/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
11/13/2024CitigroupBoost TargetBuy ➝ Buy$65.00 ➝ $68.00
11/13/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$44.00 ➝ $50.00
10/17/2024Leerink PartnersBoost TargetOutperform ➝ Outperform$47.00 ➝ $49.00
10/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
8/8/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$50.00 ➝ $60.00
8/8/2024Evercore ISIBoost TargetOutperform ➝ Outperform$62.00 ➝ $66.00
8/8/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$39.00 ➝ $44.00
7/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
7/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
6/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
6/18/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$31.00 ➝ $39.00
6/18/2024CitigroupBoost TargetBuy ➝ Buy$38.00 ➝ $64.00
6/18/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$66.00 ➝ $68.00
6/18/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$53.00 ➝ $57.00
6/17/2024Baird R WUpgradeStrong-Buy
6/17/2024HC WainwrightBoost TargetBuy ➝ Buy$58.00 ➝ $66.00
6/17/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$34.00 ➝ $39.00
6/17/2024Stifel NicolausReiterated RatingBuy ➝ Buy$48.00 ➝ $48.00
6/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$58.00 ➝ $58.00
5/10/2024Morgan StanleyLower TargetOverweight ➝ Overweight$57.00 ➝ $53.00
5/9/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$72.00 ➝ $66.00
5/9/2024CitigroupBoost TargetBuy ➝ Buy$37.00 ➝ $38.00
5/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$40.00
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$58.00
4/17/2024Stifel NicolausInitiated CoverageBuy$48.00
4/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$58.00
3/18/2024Leerink PartnersLower TargetOutperform ➝ Outperform$44.00 ➝ $43.00
3/14/2024HC WainwrightBoost TargetBuy ➝ Buy$45.00 ➝ $58.00
3/14/2024JMP SecuritiesBoost TargetOutperform ➝ Outperform$69.00 ➝ $72.00
2/29/2024HC WainwrightLower TargetBuy ➝ Buy$58.00 ➝ $45.00
2/29/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$35.00
2/29/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$64.00 ➝ $69.00
1/11/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$64.00
12/19/2023Raymond James FinancialLower TargetStrong-Buy ➝ Strong-Buy$78.00 ➝ $64.00
12/18/2023HC WainwrightLower TargetBuy ➝ Buy$60.00 ➝ $58.00
11/27/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$50.00
11/20/2023JPMorgan Chase & Co.Reiterated RatingOverweight$37.00
11/15/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$50.00
11/13/2023Morgan StanleyInitiated CoverageOverweight$60.00
11/3/2023HC WainwrightLower TargetBuy ➝ Buy$63.00 ➝ $60.00
10/24/2023Cantor FitzgeraldInitiated CoverageOverweight$50.00
10/18/2023Raymond James FinancialLower TargetStrong-Buy ➝ Strong-Buy$84.00 ➝ $77.00
10/18/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$70.00
10/17/2023Evercore ISIReiterated RatingOutperform$62.00
10/9/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$70.00
10/3/2023Robert W. BairdBoost Target$35.00 ➝ $38.00
9/20/2023JMP SecuritiesInitiated CoverageOutperform$70.00
9/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$63.00
8/21/2023Raymond James FinancialBoost TargetStrong-Buy ➝ Strong-Buy$79.00 ➝ $84.00
8/4/2023HC WainwrightReiterated RatingBuy$63.00
8/4/2023Raymond James FinancialLower TargetStrong-Buy ➝ Strong-Buy$82.00 ➝ $79.00
7/18/2023HC WainwrightBoost TargetBuy$61.00 ➝ $63.00
4/13/2023Raymond James FinancialLower TargetStrong-Buy$83.00 ➝ $81.00
4/6/2023HC WainwrightReiterated RatingBuy$61.00
3/15/2023HC WainwrightReiterated RatingBuy$61.00
3/9/2023Raymond James FinancialLower TargetStrong-Buy$84.00 ➝ $83.00
3/9/2023HC WainwrightReiterated RatingBuy$61.00
2/15/2023HC WainwrightLower TargetBuy$69.00 ➝ $61.00
1/10/2023Leerink PartnersLower TargetOutperform$50.00 ➝ $39.00
1/10/2023Raymond James FinancialLower TargetStrong-Buy$88.00 ➝ $84.00
12/14/2022Leerink PartnersBoost TargetOutperform$49.00 ➝ $50.00
11/28/2022JPMorgan Chase & Co.Lower Target$30.00
11/14/2022HC WainwrightBoost TargetBuy$68.00 ➝ $69.00
11/10/2022CitigroupLower TargetBuy$38.00 ➝ $34.00
10/25/2022Raymond James FinancialBoost TargetStrong-Buy$75.00 ➝ $88.00
10/25/2022HC WainwrightBoost TargetBuy$63.00 ➝ $68.00
9/1/2022CitigroupInitiated CoverageBuy$38.00
8/11/2022HC WainwrightLower TargetBuy$69.00 ➝ $63.00
5/24/2022Leerink PartnersBoost TargetOutperform$50.00 ➝ $52.00
5/23/2022HC WainwrightBoost TargetBuy$64.00 ➝ $69.00
4/26/2022Leerink PartnersBoost TargetOutperform$46.00 ➝ $49.00
3/11/2022Raymond James FinancialBoost TargetStrong-Buy$70.00 ➝ $74.00
1/28/2022Leerink PartnersBoost TargetOutperform$42.00 ➝ $46.00
1/12/2022Raymond James FinancialBoost TargetStrong-Buy$69.00 ➝ $70.00
9/30/2021HC WainwrightBoost TargetAverage ➝ Buy$51.00 ➝ $64.00
9/30/2021Leerink PartnersBoost TargetOutperform$32.00 ➝ $41.00
9/30/2021Raymond James FinancialBoost TargetBuy ➝ Strong-Buy$51.00 ➝ $69.00
9/30/2021Robert W. BairdBoost TargetPositive ➝ Outperform$30.00 ➝ $34.00
9/20/2021JPMorgan Chase & Co.Initiated CoverageOverweight$30.00
9/14/2021HC WainwrightLower TargetBuy$52.00 ➝ $51.00
9/14/2021Raymond James FinancialLower TargetStrong-Buy$52.00 ➝ $51.00
9/13/2021Leerink PartnersLower TargetOutperform$33.00 ➝ $32.00
8/6/2021HC WainwrightReiterated RatingBuy
8/6/2021Leerink PartnersLower TargetOutperform$38.00 ➝ $33.00
7/27/2021HC WainwrightReiterated RatingBuy$15.24
4/1/2021Robert W. BairdReiterated RatingBuy$30.00
2/8/2021Leerink PartnersInitiated CoverageOutperform$38.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 26 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 31 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 7 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 7 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 38 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 10 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 9 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 24 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 24 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Mirum Pharmaceuticals logo
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $71.53
Low: $69.86
High: $71.98

50 Day Range

MA: $71.62
Low: $67.72
High: $76.19

52 Week Range

Now: $71.53
Low: $36.88
High: $78.54

Volume

234,164 shs

Average Volume

545,564 shs

Market Capitalization

$3.68 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Mirum Pharmaceuticals?

The following sell-side analysts have issued research reports on Mirum Pharmaceuticals in the last year: Cantor Fitzgerald, Citigroup Inc., Citizens Jmp, Cowen Inc, Evercore ISI, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Morgan Stanley, Raymond James Financial, Inc., Robert W. Baird, Stifel Nicolaus, TD Cowen, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for MIRM.

What is the current price target for Mirum Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Mirum Pharmaceuticals in the last year. Their average twelve-month price target is $84.91, suggesting a possible upside of 18.7%. JMP Securities has the highest price target set, predicting MIRM will reach $95.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $55.00 for Mirum Pharmaceuticals in the next year.
View the latest price targets for MIRM.

What is the current consensus analyst rating for Mirum Pharmaceuticals?

Mirum Pharmaceuticals currently has 1 sell rating, 11 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MIRM will outperform the market and that investors should add to their positions of Mirum Pharmaceuticals.
View the latest ratings for MIRM.

What other companies compete with Mirum Pharmaceuticals?

Other companies that are similar to Mirum Pharmaceuticals include Roivant Sciences, Summit Therapeutics, BridgeBio Pharma, Viatris and Ascendis Pharma A/S. Learn More about companies similar to Mirum Pharmaceuticals.

How do I contact Mirum Pharmaceuticals' investor relations team?

Mirum Pharmaceuticals' physical mailing address is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. The company's listed phone number is (650) 667-4085 and its investor relations email address is [email protected]. The official website for Mirum Pharmaceuticals is mirumpharma.com. Learn More about contacing Mirum Pharmaceuticals investor relations.